Marriott Marquis San Diego,
Live In-Person Event: December 15 - 18, 2024
Antibody Drug Conjugate Insights
Access speaker interviews, sponsored content, and expert opinion pieces that provide actionable insights into the latest advancements in antibody-drug conjugates, including the transformative role of AI and machine learning in accelerating discovery and development. Stay informed with valuable event resources and explore key trends shaping the future of targeted ADC therapies and innovative computational approaches.
Antibody Drug Conjugates Content
First in Human Studies with ELU001, an anti-Folate Receptor Alpha Targeted C’Dot Drug Conjugate
Gregory Adams, Ph.D., Chief Scientific Officer at Elucida Oncology talks on how targeted CDCs have the ability to efficiently penetrate into solid tumors and cross the disrupted blood brain barrier to target tumors in the brain potentially addressing key limitations of ADCs. Preclinical development of an anti-tissue factor CDC targeted via single domain antibodies and phase 1 clinical results of ELU-001, an anti-folate receptor alpha CDC, will be presented.
Marika Nestor: The Future of Radioimmunotherapy
Marika Nestor, a leading figure in Biomedical Radiation Sciences at Uppsala University, discusses her groundbreaking work in radioimmunotherapy (RIT), a cutting-edge approach to cancer treatment that combines the precision of radiolabeled antibodies with the power of radiotherapy. With a focus on developing innovative radiopharmaceuticals and radiosensitizers, her team has achieved significant milestones, including a novel radiolabeled antibody now entering Phase 1 clinical trials. Nestor shares insights into the promise of RIT for addressing metastatic cancer, the challenges of optimizing tumor targeting, and the exciting potential of combination therapies and emerging technologies to revolutionize cancer care.
Clinical Experience with An HER3 DXd ADC
Pasi Jänne, M.D., Ph.D., Director at the Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute focuses on the clinical development and application of a HER3-targeted antibody-drug conjugate (ADC).
Lessons Learned from 25 years of HER2 Targeting with Trastuzumab and ADCs Based upon Trastuzumab Such as TDM1 and Enhertu
Mark Pegram, M.D., Professor of Medical Oncology at Stanford University School of Medicine focuses on the evolution of HER2-targeted therapies in cancer treatment. It reviews the clinical impact of trastuzumab and its antibody-drug conjugates (ADCs) like TDM1 and Enhertu, highlighting how these therapies have transformed outcomes in HER2-positive cancers.
Meet the experts leading Antibody Drug Conjugate Innovation
15+
FDA Approved ADC's
>90%
Target Specificity
$12B+
Market Size by 2026
40,000+
Patients treated
10+ years
of research and development
10-100x
potency compared to traditional chemotherapy
Exploring Antibody Drug Conjugates: Key Topics at Our Upcoming Event
How does MYTX-011 broaden the potential patient base for ADC therapies targeting cMET?
MYTX-011, an investigational ADC, enhances anti-tumor activity across patients with a wider spectrum of cMET expression levels, including those with lower to moderate expression. This ADC promotes better internalization and cytotoxicity with an extended pharmacokinetic profile and a reduced side-effect profile, showing robust activity in preclinical models. Brian Fiske, Ph.D., will be discussing the development of MYTX-011, an investigational ADC targeting cMET with enhanced activity against tumors expressing low to moderate levels of this receptor.
What role does chain exchange technology play in ADC development?
Chain exchange enables the development of ADC matrices by varying binders, formats, attachment positions, and payloads. This flexibility helps in optimizing ADC function, revealing that format selection can significantly impact efficacy and specificity, similar to bispecific antibodies. Ulrich Brinkmann, will be exploring how chain exchange technology is advancing ADC development by enabling the creation of matrices combining various binders, payloads, and formats.
How can a dual-payload ADC platform overcome drug resistance in HER2+ cancers?
Dual-payload ADCs like those developed by Hummingbird Bioscience combat resistance by deploying two cytotoxic agents in a single molecule, targeting cancer cells more effectively, even in resistant models. This approach enhances the therapeutic window while maintaining tolerability. Jerome Boyd-Kirkup, Ph.D., will be presenting Hummingbird Bioscience's dual-payload ADC platform, which addresses payload resistance, a common challenge in cancer therapies.
What is the CAPAC platform, and how does it enhance ADC targeting?
The CAPAC platform selectively activates ADC payloads at the tumor site, reducing systemic toxicity. This innovation represents a significant advance for ADCs by enhancing therapeutic index and improving patient safety profiles. José M. Mejía Oneto, M.D., Ph.D., will be talking on the CAPAC (Click Activated Protodrugs Against Cancer) platform, which activates ADCs at the tumor site using click chemistry.
What potentiation strategies are being explored to improve radioimmunotherapy efficacy?
Research into radioimmunotherapy potentiation includes strategies such as combination therapies and antibody modifications to improve efficacy and reduce toxicity. These enhancements aim to address the challenges of radioimmunotherapy, such as prolonged radioactivity exposure. Marika Nestor, Ph.D., will be examining potentiation strategies for radioimmunotherapy (RIT), including antibody modifications and combination therapies.
How can FcγR-ablated TLR7 agonist ADCs reduce immune side effects?
FcγR-ablated TLR7 agonist ADCs avoid FcγR binding to reduce off-target immune activation. This approach maintains effective tumor-specific immune activation while reducing immune-related side effects, with promising results in breast and pancreatic cancer models. Anqi Zhang, Ph.D. will be discussing the development of FcγR-ablated TLR7 agonist ADCs, which minimize immune side effects by bypassing Fcγ receptor interactions.
